Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Evaluating the Phase 2 data on PEGPH20 in Advanced Pancreatic Cancer

Ticker(s): HALO

Who's the expert?

Name: Dr Joseph Herman - MD

Institution: MD Anderson Cancer Center

Bio:

  • Radiation oncologist who treats several hundred patients with Advanced Pancreas Cancer per year.
  • His research has led to new standards in care, and he is the founder of a unique one-day clinic for pancreatic cancer patients who need treatment recommendations from all branches of cancer care.
  • Extensively published on both therapeutic and radiological treatments and familiar with the PEGPH20 program as well as FDA's perspective and expectations around Pancreatic Cancer Treatments in development.

Interview Questions
Q1.

Please describe your clinical practice and experience with clinical trials in Pancreatic Cancer.

Added By: joe_mccann
Q2.

What are your overall impressions of the PEGPH20 data?

Added By: joe_mccann
Q3.

What is the likelihood that Progression Free Survival is sufficient for the FDA rather than Overall Survival?

Added By: joe_mccann
Q4.

How will the FDA treat overall response rate (ORR) data?

Added By: joe_mccann
Q5.

Is this too far off the cusp for the current FDA assuming no change at the top (which I expect but cannot depend on)?

Added By: joe_mccann
Q6.

Will the P-value and hazard rate seen in phase II cause pause for the FDA?

Added By: joe_mccann
Q7.

Is the trial design sufficient to allow for a clean progression to Phase III or, as some have claimed, there is too much hair or apparent concern with the exploratory design of the trial to proceed without major reservations from the FDA?

Added By: joe_mccann
Q8.

How familiar are you with HALO’s history vs this specific trial? What is your opinion of the company and management to the extent you have one?

Added By: joe_mccann
Q9.

How do you think about the The protocol amendment in 2014 around Thromboembolic Events (TE). Slide 10 of the company recent presentation showed the TE rates for the 2 arms. How do these numbers for Stage 2 vs. Stage 1 look to you?  How concerned about TE are you with PEGPH20?

Added By: joe_mccann
Q10.

In your experience is there a clotting risk in pancreatic patients independent of this drug which could have been exacerbated by PEGPH20 in the first trial, that was stopped for clotting issues? 

Added By: neuman101
Q11.

How do you look at the PFS vs. OS rates in a study like 202? I ask mainly because the OS HR was .96, while the PFS was only .51.  Does the OS HR concern you here? If it does not concern you, why not? (Slide 12)

Added By: joe_mccann
Q12.

Do you think it is best to focus on OS and PFS for Stage 2 only or Stage 1 + 2 combined? The company does an exploratory analysis on the Stage 2 alone and the Hazard ratios look much better.

Added By: joe_mccann

Are You Interested In These Questions?

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.